董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Arie Mayer | -- | Director | 67 | 40.13万美元 | 未持股 | 2023-05-31 |
| Yadin Rozov | 男 | Director | 45 | 17.89万美元 | 未持股 | 2023-05-31 |
| Benjamin Shapiro | 男 | Director | 39 | 未披露 | 未持股 | 2023-05-31 |
| Nadav Kidron | 男 | President, Chief Executive Officer, Director and Chairman | 48 | 683.36万美元 | 258.43 | 2023-05-31 |
| Miriam Kidron | 女 | Chief Scientific Officer and Director | 82 | 307.02万美元 | 32.46 | 2023-05-31 |
| Leonard Sank | 男 | Director | 58 | 30.60万美元 | 58.05 | 2023-05-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Silberman | 男 | Chief Financial Officer and Treasurer | 39 | 126.92万美元 | 未持股 | 2023-05-31 |
| Michael Rabinowitz | 男 | Chief Commercial Officer | 57 | 未披露 | 未持股 | 2023-05-31 |
| Netanel Derovan | 男 | Chief Legal Officer and Secretary | 48 | 未披露 | 未持股 | 2023-05-31 |
| Nadav Kidron | 男 | President, Chief Executive Officer, Director and Chairman | 48 | 683.36万美元 | 258.43 | 2023-05-31 |
| Miriam Kidron | 女 | Chief Scientific Officer and Director | 82 | 307.02万美元 | 32.46 | 2023-05-31 |
| Joshua Hexter | 男 | Chief Operating & Business Officer | 53 | 60.88万美元 | 17.83 | 2023-05-31 |
董事简历
中英对照 | 中文 | 英文- Arie Mayer
-
Arie Mayer于2019年12月成为董事。Mayer博士目前是Merck Life Science Israel（前身为Sigma-Aldrich Israel Ltd.）的常务董事兼董事会主席，自2010年1月起担任该职位。Mayer自1995年起在Sigma-Aldrich Israel Ltd.担任多个职位，在Sigma Aldrich Israel Ltd.引入和发展细胞培养和分子生物学业务方面发挥了重要作用。Mayer博士拥有希伯来大学（Hebrew University）化学理学学士学位和以色列理工学院（Israel Institute of Technology）生物化学博士学位。
Arie Mayer,became a director in December 2019. Dr. Mayer is currently the Managing Director and Chairman of the Board of Sigma-Aldrich Israel Ltd. and has held that position since January 2010. Dr. Mayer has held various roles with Sigma-Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developing the Cell Culture and Molecular Biology business for Sigma Aldrich Israel Ltd. Dr. Mayer holds a Bachelor of Science degree in chemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology. - Arie Mayer于2019年12月成为董事。Mayer博士目前是Merck Life Science Israel（前身为Sigma-Aldrich Israel Ltd.）的常务董事兼董事会主席，自2010年1月起担任该职位。Mayer自1995年起在Sigma-Aldrich Israel Ltd.担任多个职位，在Sigma Aldrich Israel Ltd.引入和发展细胞培养和分子生物学业务方面发挥了重要作用。Mayer博士拥有希伯来大学（Hebrew University）化学理学学士学位和以色列理工学院（Israel Institute of Technology）生物化学博士学位。
- Arie Mayer,became a director in December 2019. Dr. Mayer is currently the Managing Director and Chairman of the Board of Sigma-Aldrich Israel Ltd. and has held that position since January 2010. Dr. Mayer has held various roles with Sigma-Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developing the Cell Culture and Molecular Biology business for Sigma Aldrich Israel Ltd. Dr. Mayer holds a Bachelor of Science degree in chemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology.
- Yadin Rozov
-
亚丁罗佐夫于2022年4月成为董事。自2022年1月起，罗佐夫成为金融咨询公司Terrace Edge Ventures LLC的创始人和管理合伙人。从2019年到2021年，罗佐夫先生是全球领先的信贷资产管理公司GoldenTree Asset Management LLC的合伙人。从2019年至2021年，Rozov先生还担任Syncora Guarantee Inc.的首席执行官兼总裁，从2020年至2021年，担任Financial Guaranty UK Ltd的首席执行官，这两家公司都是GoldenTree旗下的独立专业保险公司。2009年至2019年，他在Moelis & Company担任合伙人兼董事总经理，领导金融机构咨询小组，并担任Moelis Asset Management管理委员会成员。从2014年到2019年，罗佐夫帮助共同创立了College Avenue Student Loans LLC，并在其董事会任职，并共同创立了Chamonix Partners Capital Management LLC。2007年至2009年，Rozov先生担任UBS公司董事总经理，并担任重新定位小组美洲主管。Rozov先生自2022年6月起担任Midwest Holding Inc.董事会成员，自2022年8月起担任Neo Performance Materials Inc.董事会成员。Rozov先生拥有哥伦比亚大学数据科学硕士学位和罗格斯大学物理和材料工程最高荣誉学士学位。
Yadin Rozov,became a director in April 2022. Mr. Rozov is the founder and managing partner of Terrace Edge Ventures LLC, a financial advisory firm, since January 2022. From 2019 to 2021, Mr. Rozov was a Partner of GoldenTree Asset Management LLC, a leading global credit asset management firm. From 2019 to 2021, Mr. Rozov also served as the Chief Executive Officer and President of Syncora Guarantee Inc. and from 2020 to 2021, as Chief Executive Officer of Financial Guaranty UK Ltd, each of which is a stand-alone specialty insurance company owned by GoldenTree. From 2009 to 2019, he was a Partner and Managing Director at Moelis & Company where he headed the Financial Institution Advisory group and was on the Management Committee of Moelis Asset Management. From 2014 to 2019, Mr. Rozov helped co-found College Avenue Student Loans LLC and served on its board and co-founded Chamonix Partners Capital Management LLC. From 2007 to 2009, Mr. Rozov was a Managing Director at UBS AG, where he was the Head of the Americas for the Repositioning Group. Mr. Rozov has served on the board of directors of Midwest Holding Inc. since June 2022, and on the board of directors of Neo Performance Materials Inc. since August 2022. Mr. Rozov holds an M.Sc. in data science from Columbia University and a bachelor's degree with highest honors in physics and materials engineering from Rutgers University. - 亚丁罗佐夫于2022年4月成为董事。自2022年1月起，罗佐夫成为金融咨询公司Terrace Edge Ventures LLC的创始人和管理合伙人。从2019年到2021年，罗佐夫先生是全球领先的信贷资产管理公司GoldenTree Asset Management LLC的合伙人。从2019年至2021年，Rozov先生还担任Syncora Guarantee Inc.的首席执行官兼总裁，从2020年至2021年，担任Financial Guaranty UK Ltd的首席执行官，这两家公司都是GoldenTree旗下的独立专业保险公司。2009年至2019年，他在Moelis & Company担任合伙人兼董事总经理，领导金融机构咨询小组，并担任Moelis Asset Management管理委员会成员。从2014年到2019年，罗佐夫帮助共同创立了College Avenue Student Loans LLC，并在其董事会任职，并共同创立了Chamonix Partners Capital Management LLC。2007年至2009年，Rozov先生担任UBS公司董事总经理，并担任重新定位小组美洲主管。Rozov先生自2022年6月起担任Midwest Holding Inc.董事会成员，自2022年8月起担任Neo Performance Materials Inc.董事会成员。Rozov先生拥有哥伦比亚大学数据科学硕士学位和罗格斯大学物理和材料工程最高荣誉学士学位。
- Yadin Rozov,became a director in April 2022. Mr. Rozov is the founder and managing partner of Terrace Edge Ventures LLC, a financial advisory firm, since January 2022. From 2019 to 2021, Mr. Rozov was a Partner of GoldenTree Asset Management LLC, a leading global credit asset management firm. From 2019 to 2021, Mr. Rozov also served as the Chief Executive Officer and President of Syncora Guarantee Inc. and from 2020 to 2021, as Chief Executive Officer of Financial Guaranty UK Ltd, each of which is a stand-alone specialty insurance company owned by GoldenTree. From 2009 to 2019, he was a Partner and Managing Director at Moelis & Company where he headed the Financial Institution Advisory group and was on the Management Committee of Moelis Asset Management. From 2014 to 2019, Mr. Rozov helped co-found College Avenue Student Loans LLC and served on its board and co-founded Chamonix Partners Capital Management LLC. From 2007 to 2009, Mr. Rozov was a Managing Director at UBS AG, where he was the Head of the Americas for the Repositioning Group. Mr. Rozov has served on the board of directors of Midwest Holding Inc. since June 2022, and on the board of directors of Neo Performance Materials Inc. since August 2022. Mr. Rozov holds an M.Sc. in data science from Columbia University and a bachelor's degree with highest honors in physics and materials engineering from Rutgers University.
- Benjamin Shapiro
-
本杰明·夏皮罗，于2023年5月成为董事。夏皮罗是一位成功的企业家和商业专业人士，他于2015年6月与人共同创立了The Daily Wire，这是一家成功的、行业领先的国际媒体机构。自2015年5月以来，他一直担任热门播客《本·夏皮罗秀》的主持人，并著有多本《纽约时报》畅销书。夏皮罗于2004年以优异成绩获得加州大学洛杉矶分校政治学学士学位，并于2007年以优异成绩获得哈佛法学院法学学位。
Benjamin Shapiro,became a director in May 2023. Mr. Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he has been host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned a B.A. in Political Science from UCLA in 2004, summa cum laude, and a law degree from Harvard Law School in 2007, cum laude. - 本杰明·夏皮罗，于2023年5月成为董事。夏皮罗是一位成功的企业家和商业专业人士，他于2015年6月与人共同创立了The Daily Wire，这是一家成功的、行业领先的国际媒体机构。自2015年5月以来，他一直担任热门播客《本·夏皮罗秀》的主持人，并著有多本《纽约时报》畅销书。夏皮罗于2004年以优异成绩获得加州大学洛杉矶分校政治学学士学位，并于2007年以优异成绩获得哈佛法学院法学学位。
- Benjamin Shapiro,became a director in May 2023. Mr. Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he has been host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned a B.A. in Political Science from UCLA in 2004, summa cum laude, and a law degree from Harvard Law School in 2007, cum laude.
- Nadav Kidron
-
Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
Nadav Kidron,was appointed President, Chief Executive Officer and director in March 2006, and Chairman of the Board effective as of June 30, 2022. He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel. - Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
- Nadav Kidron,was appointed President, Chief Executive Officer and director in March 2006, and Chairman of the Board effective as of June 30, 2022. He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel.
- Miriam Kidron
-
Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
Miriam Kidron,was appointed Chief Scientific Officer and director in March 2006. Dr. Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. - Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
- Miriam Kidron,was appointed Chief Scientific Officer and director in March 2006. Dr. Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.
- Leonard Sank
-
Leonard Sank，于2007年10月被任命为董事。他是一位南非的（South African）企业家和商人，致力于创业活动和倡议。他拥有着超过20年的在发展公司中扮演重要角色的经历。自2011年12月以来，他在一家多元化零售汽车公司- Eastvaal Motors Pty有限公司担任董事；以及曾在过去担任过该公司的董事。自2010年以来，他在Bradbury Finance Pty有限公司担任董事。2000-2007年期间，他在一家信贷公司- Vecto Finance Pty有限公司担任董事。在过去的15年里，他曾在南非（South Africa）最大的私营公司- Macsteel Service Centres SA Pty有限公司担任董事。他目前还在开普敦市（Cape Town，他住的地方）一些小公司和当地非盈利慈善组织的董事会任职。
Leonard Sank,became a director in October 2007. Mr. Sank is a South African entrepreneur and businessman, whose interests lie in entrepreneurial endeavors and initiatives. Mr. Sank serves on the boards of a few national businesses and local non-profit charity organizations in Cape Town, where he resides. - Leonard Sank，于2007年10月被任命为董事。他是一位南非的（South African）企业家和商人，致力于创业活动和倡议。他拥有着超过20年的在发展公司中扮演重要角色的经历。自2011年12月以来，他在一家多元化零售汽车公司- Eastvaal Motors Pty有限公司担任董事；以及曾在过去担任过该公司的董事。自2010年以来，他在Bradbury Finance Pty有限公司担任董事。2000-2007年期间，他在一家信贷公司- Vecto Finance Pty有限公司担任董事。在过去的15年里，他曾在南非（South Africa）最大的私营公司- Macsteel Service Centres SA Pty有限公司担任董事。他目前还在开普敦市（Cape Town，他住的地方）一些小公司和当地非盈利慈善组织的董事会任职。
- Leonard Sank,became a director in October 2007. Mr. Sank is a South African entrepreneur and businessman, whose interests lie in entrepreneurial endeavors and initiatives. Mr. Sank serves on the boards of a few national businesses and local non-profit charity organizations in Cape Town, where he resides.
高管简历
中英对照 | 中文 | 英文- David Silberman
David Silberman于2006年3月被任命为首席科学官和主任。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷哈大沙大学医院糖尿病部门的高级研究员。在2003年和2004年期间，Kidron博士担任Emisphere Technologies Inc.的顾问，该公司专注于开发基础广泛的专有药物输送平台。Kidron博士曾是加拿大多伦多大学医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。基德隆博士是伯尔尼·施兰格奖的获得者。
David Silberman,was appointed Chief Financial Officer and Treasurer in July 2021. Prior to his appointment, from April 2018 to May 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis associate director and director at Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. From 2014 to 2018, Mr. Silberman served as Global Internal Audit senior manager at Teva Pharmaceutical Industries Ltd. From 2009 to 2014, Mr. Silberman provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. From January 2009 until June 2009, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm. Mr. Silberman holds DCG and DSCG degrees from the French Ministry of Higher Study and Research and is a certified public accountant in Israel.- David Silberman于2006年3月被任命为首席科学官和主任。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷哈大沙大学医院糖尿病部门的高级研究员。在2003年和2004年期间，Kidron博士担任Emisphere Technologies Inc.的顾问，该公司专注于开发基础广泛的专有药物输送平台。Kidron博士曾是加拿大多伦多大学医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。基德隆博士是伯尔尼·施兰格奖的获得者。
- David Silberman,was appointed Chief Financial Officer and Treasurer in July 2021. Prior to his appointment, from April 2018 to May 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis associate director and director at Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. From 2014 to 2018, Mr. Silberman served as Global Internal Audit senior manager at Teva Pharmaceutical Industries Ltd. From 2009 to 2014, Mr. Silberman provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. From January 2009 until June 2009, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm. Mr. Silberman holds DCG and DSCG degrees from the French Ministry of Higher Study and Research and is a certified public accountant in Israel.
- Michael Rabinowitz
任命之前，1993年6月至2021年2月，Michael Rabinowitz先生在全球生物制药公司默克公司担任过各种市场营销，销售，业务发展和财务领导职务，他在该公司在多个疾病领域的30多个国家/地区推出和销售产品，包括推出数十亿美元的糖尿病口服制剂和管理全球业务。Rabinowitz先生拥有明尼苏达大学卡尔森管理学院的硕士学位。他还参加了哈佛商学院的高管医疗保健项目。
Michael Rabinowitz,was appointed Chief Commercial Officer in August 2021. Prior to his appointment, Mr. Rabinowitz served for over 25 years, from 1993 to 2021, in various marketing, sales, business development, and financial leadership roles at the global biopharmaceutical company Merck & Co., where he launched and marketed products in over 30 countries across several disease areas, including launching billion-dollar oral agents in diabetes and managing a global business. Mr. Rabinowitz holds a bachelors' degree summa cum laude from Northwestern University and a masters' degree from The Carlson School of Management at the University of Minnesota. He has also participated in executive health care programs at the Harvard Business School and the Wharton School of the University of Pennsylvania.- 任命之前，1993年6月至2021年2月，Michael Rabinowitz先生在全球生物制药公司默克公司担任过各种市场营销，销售，业务发展和财务领导职务，他在该公司在多个疾病领域的30多个国家/地区推出和销售产品，包括推出数十亿美元的糖尿病口服制剂和管理全球业务。Rabinowitz先生拥有明尼苏达大学卡尔森管理学院的硕士学位。他还参加了哈佛商学院的高管医疗保健项目。
- Michael Rabinowitz,was appointed Chief Commercial Officer in August 2021. Prior to his appointment, Mr. Rabinowitz served for over 25 years, from 1993 to 2021, in various marketing, sales, business development, and financial leadership roles at the global biopharmaceutical company Merck & Co., where he launched and marketed products in over 30 countries across several disease areas, including launching billion-dollar oral agents in diabetes and managing a global business. Mr. Rabinowitz holds a bachelors' degree summa cum laude from Northwestern University and a masters' degree from The Carlson School of Management at the University of Minnesota. He has also participated in executive health care programs at the Harvard Business School and the Wharton School of the University of Pennsylvania.
- Netanel Derovan
Netanel Derovan于2022年1月被任命为首席法务官兼秘书。在被任命之前，2012年至2021年，Derovan先生在梯瓦制药工业有限公司法务部担任公司和证券执行法律顾问。2004年至2012年，他在Goldfarb Seligman & Co国际公司和证券部担任高级法律顾问。2002年至2004年，他在Caspi & Co国际公司部担任助理律师。2001年至2002年，他在Gornitzky & Co担任法律实习生。Derovan先生拥有巴伊兰大学法学学士学位，并且是Israel Bar协会的成员。
Netanel Derovan,was appointed Chief Legal Officer and Secretary in January 2022. Prior to his appointment, from 2012 to 2021, Mr. Derovan served as executive counsel, corporate and securities, in the legal department of Teva Pharmaceutical Industries Ltd. From 2004 to 2012, he served as senior counsel in the International Corporate and Securities Department of Goldfarb Seligman & Co. From 2002 to 2004, he served as an associate attorney in the International Corporate Department at Caspi & Co. From 2001 to 2002, he served as a legal intern at Gornitzky & Co. Mr. Derovan holds an LL.B. degree from Bar Ilan University and is a member of the Israel Bar Association.- Netanel Derovan于2022年1月被任命为首席法务官兼秘书。在被任命之前，2012年至2021年，Derovan先生在梯瓦制药工业有限公司法务部担任公司和证券执行法律顾问。2004年至2012年，他在Goldfarb Seligman & Co国际公司和证券部担任高级法律顾问。2002年至2004年，他在Caspi & Co国际公司部担任助理律师。2001年至2002年，他在Gornitzky & Co担任法律实习生。Derovan先生拥有巴伊兰大学法学学士学位，并且是Israel Bar协会的成员。
- Netanel Derovan,was appointed Chief Legal Officer and Secretary in January 2022. Prior to his appointment, from 2012 to 2021, Mr. Derovan served as executive counsel, corporate and securities, in the legal department of Teva Pharmaceutical Industries Ltd. From 2004 to 2012, he served as senior counsel in the International Corporate and Securities Department of Goldfarb Seligman & Co. From 2002 to 2004, he served as an associate attorney in the International Corporate Department at Caspi & Co. From 2001 to 2002, he served as a legal intern at Gornitzky & Co. Mr. Derovan holds an LL.B. degree from Bar Ilan University and is a member of the Israel Bar Association.
- Nadav Kidron
Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
Nadav Kidron,was appointed President, Chief Executive Officer and director in March 2006, and Chairman of the Board effective as of June 30, 2022. He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel.- Nadav Kidron，于2006年3月被任命为总裁、首席执行官和董事。他还是该公司拥有3%流通股的Entera公司的一位董事。2009年，他曾是美国-以色列（U.S。-Israel）生命科学领域高管贸易项目Merage 基金会的一位会员。2003-2006年期间，他曾是Bar Ilan大学先进犹太学研究协会（Institute of Advanced Jewish Studies）的一位常务董事。2001-2003年期间，他曾是以色列（Israel）耶路撒冷（Jerusalem）Wine, Mishaiker & Ernstoff律师事务所的一位法律实习生。他拥有以色列（Israel）Bar Ilan大学的法学学士学位、国际工商管理硕士学位；以及是以色列（Israel）律师协会的一位成员。
- Nadav Kidron,was appointed President, Chief Executive Officer and director in March 2006, and Chairman of the Board effective as of June 30, 2022. He is also a director of Israel Advanced Technology Industries organization, and until 2016 was a director of Entera Bio Ltd. In 2009, he was a fellow at the Merage Foundation for U.S.-Israel Trade Programs for executives in the life sciences field. From 2003 to 2006, he was the managing director of the Institute of Advanced Jewish Studies at Bar Ilan University. From 2001 to 2003, he was a legal intern at Wine, Mishaiker & Ernstoff Law Offices in Jerusalem, Israel. Mr. Kidron holds an LL.B. and an International MBA from Bar Ilan University, Israel.
- Miriam Kidron
Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
Miriam Kidron,was appointed Chief Scientific Officer and director in March 2006. Dr. Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.- Miriam Kidron， 2006年3月被任命为首席科学官兼董事。Kidron博士是一名药理学家和生物化学家，拥有生物化学博士学位。从1990年到2007年，Kidron博士是以色列耶路撒冷Hadassah University Hospital糖尿病部门的高级研究员。Kidron博士曾是多伦多大学（加拿大）医学院的客座教授，也是美国、欧洲和以色列糖尿病协会的成员。她是Bern Schlanger奖的获得者。
- Miriam Kidron,was appointed Chief Scientific Officer and director in March 2006. Dr. Kidron is a pharmacologist and a biochemist with a Ph.D. in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award.
- Joshua Hexter
Joshua Hexter， 于2013年4月被任命为首席运营官和商业开发副总裁。2007-2013年期间，在一家致力于识别、授权和开发创新疗法药物的生物医药开发公司- BioLineRx有限公司“BioLine”（TASE： BLRX）的一位董事或者执行董事。在BioLine任职之前，他曾是一家发展市场导向生物感测器的公司- Biosensor Systems Design股份有限公司的一位董事会成员和首席执行官。他拥有Wisconsin大学的学士学位，以及波士顿大学（Boston University）的管理学硕士学位。
Joshua Hexter,was appointed Chief Operating & Business Officer in September 2019. Prior to his appointment, Mr. Hexter served as Chief Business Officer at BrainsWay Ltd. (Nasdaq/TASE: BWAY) from 2018 to 2019, a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products. From 2013 to 2018, Mr. Hexter served as Chief Operating Officer and VP Business Development of the Company and from 2007 to 2013, Mr. Hexter was a Director or Executive Director of BioLineRx Ltd. (Nasdaq/TASE: BLRX), a biopharmaceutical development company dedicated to identifying, in-licensing and developing innovative therapeutic candidates. Prior to his employment with BioLineRx, Mr. Hexter was a member of the board of directors and Chief Executive Officer of Biosensor Systems Design, Inc., a company developing market-driven biosensors. Mr. Hexter holds a bachelor's degree from the University of Wisconsin and a master's degree in management from Boston University.- Joshua Hexter， 于2013年4月被任命为首席运营官和商业开发副总裁。2007-2013年期间，在一家致力于识别、授权和开发创新疗法药物的生物医药开发公司- BioLineRx有限公司“BioLine”（TASE： BLRX）的一位董事或者执行董事。在BioLine任职之前，他曾是一家发展市场导向生物感测器的公司- Biosensor Systems Design股份有限公司的一位董事会成员和首席执行官。他拥有Wisconsin大学的学士学位，以及波士顿大学（Boston University）的管理学硕士学位。
- Joshua Hexter,was appointed Chief Operating & Business Officer in September 2019. Prior to his appointment, Mr. Hexter served as Chief Business Officer at BrainsWay Ltd. (Nasdaq/TASE: BWAY) from 2018 to 2019, a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products. From 2013 to 2018, Mr. Hexter served as Chief Operating Officer and VP Business Development of the Company and from 2007 to 2013, Mr. Hexter was a Director or Executive Director of BioLineRx Ltd. (Nasdaq/TASE: BLRX), a biopharmaceutical development company dedicated to identifying, in-licensing and developing innovative therapeutic candidates. Prior to his employment with BioLineRx, Mr. Hexter was a member of the board of directors and Chief Executive Officer of Biosensor Systems Design, Inc., a company developing market-driven biosensors. Mr. Hexter holds a bachelor's degree from the University of Wisconsin and a master's degree in management from Boston University.